| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446299 | European Journal of Cancer | 2012 | 8 Pages |
Abstract
Low- and intermediate-risk patients treated with definitive RT are unlikely to die of PC. PCSM is higher in men with high-risk disease but may be reduced with dose-escalation and ADT, although patients are still twice as likely to die of other causes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Michelle M. Kim, Karen E. Hoffman, Lawrence B. Levy, Steven J. Frank, Thomas J. Pugh, Seungtaek Choi, Quynh N. Nguyen, Sean E. McGuire, Andrew K. Lee, Deborah A. Kuban,